<DOC>
	<DOCNO>NCT00936195</DOCNO>
	<brief_summary>To assess maternal infant safety single daily fixed-dose combination TDF/FTC/EFV ( Atripla® ) , compare association LPV/r ( Kaletra® Aluvia® ) 3TC/ZDV ( Combivir® ) give African woman prevent overall MTCT population practice breastfeeding .</brief_summary>
	<brief_title>Universal Use EFV-TDF-FTC AZT-3TC-LPV/r Combinations HIV-1 PMTCT Pregnant Breastfeeding Women : Phase 3 Trial</brief_title>
	<detailed_description>The prevention MTCT pregnancy breastfeeding exposure remain challenge date resource-limited setting . Peripartum HIV transmission already amenable ARV intervention . These ARV regimen , partially efficacious insufficiently use despite apparent simplicity . The postnatal transmission via breastfeeding remain serious additional threat . This multicentric , non-inferiority , randomize control trial aim assess maternal infant safety single daily fixed-dose combination TDF/FTC/EFV ( Atripla® ) , compare association LPV/r ( Kaletra® Aluvia® ) 3TC/ZDV ( Combivir® ) give African woman ( Cote d'Ivoire Zambia ) prevent MTCT overall breastfeeding population . The fixed-dose combination Tenofovir/Emtricitabine/Efavirenz ( TDF/FTC/EFV Atripla® ) highly effective HAART combination simple ARV regimen currently available resource-limited setting therefore likely become soon lead first-line HAART regimen adult setting . Its anticipated widespread prescription woman childbearing age require proper documentation use pregnancy breastfeeding . The combination ZDV/3TC ( Combivir® ) Lopinavir/ritonavir ( LPV/r ) ( Kaletra® Aluvia® ) choose reference regimen one commonly use first-line HAART adult reference regimen PMTCT industrialise setting . The maternal ARV regimen initiate soon possible 20 week gestation least cessation breastfeeding ( advice cease six month ) . The decision stop continue maternal ARV regimen breastfeed cessation base baseline maternal CD4 count maternal clinical stage baseline and/or breastfeed cessation . A woman baseline CD4 &lt; 500 cells/ml always propose continue treatment breastfeed cessation . A woman baseline CD4 count &gt; 500 ask stop treatment breastfeed cessation unless reach WHO clinical stage IV time . Infants receive daily Zidovudine syrup birth first week life , updated ARV post-exposure prophylaxis recommend WHO woman receive HAART .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>pregnant , present least 20th week pregnancy later 2 week expected term ; least 18 year age ; diagnose infected HIV1 ; currently take ARV drug ; expose NVP 6 month precede enrolment ; willing breastfeed forthcoming child ; reside planning continue reside within predefined catchment area 12 month delivery ; able give inform consent enrolment study ; lack medical contraindication propose ARV medication ; accept principle randomize receive one ARV regimens evaluate within study , prevent MTCT health require . present within 2 week expected term ; currently take ARV drug ; expose NVP 6 month precede enrolment ; willing breastfeed forthcoming child ; severe renal insufficiency ( creatin clearance &lt; 60ml/min ) ; diagnose infected HIV2 dually infect HIV1 HIV2 ; hemoglobin &lt; 7 g/dL month precede inclusion HBs Ag positive Women meet one three last exclusion criterion ( HIV2 infection coinfection , hemoglobin &lt; 7 g/dL , HBs Ag positive ) randomize receive Atripla followedup ancillary open cohort accord procedure agenda .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>pregnancy</keyword>
	<keyword>breastfeeding</keyword>
	<keyword>PMTCT</keyword>
	<keyword>ARV treatment</keyword>
	<keyword>treatment naive</keyword>
</DOC>